MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

156.20
+4.30
+2.83%
After Hours: 156.20 0 0.00% 18:57 08/07 EDT
OPEN
152.25
PREV CLOSE
151.90
HIGH
157.38
LOW
149.01
VOLUME
226.22K
TURNOVER
--
52 WEEK HIGH
257.97
52 WEEK LOW
70.00
MARKET CAP
5.19B
P/E (TTM)
-15.8701
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RETA stock price target is 269.00 with a high estimate of 345.00 and a low estimate of 172.00.

EPS

RETA News

More
Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020
PLANO, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on its develop
GlobeNewswire · 5d ago
Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors
PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effe
GlobeNewswire · 07/30 20:05
NYU launches study of Reata's bardoxolone in COVID-19
Seeking Alpha · 07/28 13:33
Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19
PLANO, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that researchers at NYU Grossman School of Medicine (“NYU”), led by Sripal
GlobeNewswire · 07/28 10:45
Blackstone's Life Sciences fund final close at $4.6B; strategic investments snapshot
Blackstone (BX -2.1%) says its Blackstone Life Sciences V was oversubscribed and final close is at its hard cap of $4.6B of total capital commitments, maki
seekingalpha · 07/10 01:07
Reata Announces Promotion and New Hires For Key Leadership Roles
GlobeNewswire · 07/07 11:45
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Reata Pharmaceuticals, Inc.- RETA
Newsfile · 07/03 21:53
Reata Pharmaceuticals, Inc. Closes $350 Million Strategic Investment From Blackstone Life Sciences
This financing includes $300 million in return for single-digit royalty payments on worldwide net sales of bardoxolone methyl (“bardoxolone”) by Reata and its licensees, other than Kyowa Kirin Co., Ltd., and a $50 million investment in 340,793 shares of Reata’
GlobeNewswire · 06/24 14:10

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About RETA

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
More

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.